Federal Register / Vol. 90, No. 3 / Monday, January 6, 2025 / Notices 655 

TABLE 2—FOOD CONTACT NOTIFICATIONS (FCNS) NO LONGER EFFECTIVE AS OF JANUARY 6, 2025 WITH A COMPLIANCE

DATE OF JUNE 30, 2025 

FCN No. FCS Manufacturer/supplier 

599 .............. Copolymer of perfluorohexylethyl methacrylate, 2-N,N-diethylaminoethyl methacrylate, 2-hydroxyethyl methacrylate, and 2,2’-ethylenedioxydiethyl dimethacrylate, acetic acid salt (CAS Reg. No. 863408–20–2) or 

malic acid salt (CAS Reg. No. 1225273–44–8).

Asahi Glass Co., Ltd. (Manufacturer) 

and AGC Chemicals Americas, Incorporated. 

604 .............. Copolymer of perfluorohexylethyl methacrylate, 2-N,N-diethylaminoethyl methacrylate, 2-hydroxyethyl methacrylate, and 2,2’-ethylenedioxydiethyl dimethacrylate, acetic acid salt (CAS Reg. No. 863408–20–2) or 

malic acid salt (CAS Reg. No. 1225273–44–8).

Asahi Glass Co., Ltd. (Manufacturer) 

and AGC Chemicals Americas, Incorporated. 

1186 ............ Butanedioic acid, 2-methylene-, polymer with 2-hydroxyethyl, 2-methyl-2-propenoate, 2-methyl-2-propenoic 

acid and 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl 2-methyl-2-propenoate, sodium salt (CAS Reg. No. 

1345817–52–8).

Asahi Glass Co., Ltd. 

AGC Chemicals Americas, Inc. 

1676 ............ 2-propenoic acid, 2-methyl-, 2-hydroxyethyl ester, polymer with 2-propenoic acid and 3,3,4,4,5,5,6,6,7,7,8,8,8-

tridecafluorooctyl 2-methyl-2-propenoate, sodium salt (CAS Reg. No. 1878204–24–0).

Asahi Glass Co., Ltd. 

AGC Chemicals Americas, Inc. 

To reflect these changes in status of 

the affected FCNs, we established an 

Inventory of Food Contact Notifications 

That are No Longer Effective on FDA’s 

website. The Inventory may be viewed 

at https://www.hfpappexternal.fda.gov/ 

scripts/fdcc/index.cfm?set=FCN-nolonger-effective. 

We also updated our Inventory of 

Effective Food Contact Notifications 

accordingly at https://www.hfpapp

external.fda.gov/scripts/fdcc/ 

index.cfm?set=FCN. 

A food additive is deemed unsafe 

unless that substance and its use 

conform with a regulation issued under 

section 409 of the Federal Food, Drug, 

and Cosmetic Act (FD&C Act) (21 U.S.C. 

348) or there is an FCN submitted under 

section 409(h) of the FD&C Act that is 

effective (section 409(a) of the FD&C 

Act). An effective FCN is specific only 

to the intended use of the substance 

prepared by the manufacturer or 

supplier identified in the FCN (section 

409(h)(1)(C)). 

Our determination that an FCN is no 

longer effective does not preclude any 

manufacturers or suppliers from 

submitting a new FCN for the same FCS, 

including for the same intended use, 

after FDA has determined that an FCN 

is no longer effective, unless the 

intended use of the FCS is authorized by 

a food additive regulation or the subject 

of an issued threshold of regulation 

exemption, per 21 CFR 170.105(c). 

II. Analysis of Environmental Impact 

We have determined under 21 CFR 

25.32(m) that this action is of a type that 

does not individually or cumulatively 

have a significant effect on the human 

environment. Therefore, neither an 

environmental assessment nor an 

environmental impact statement is 

required. 

III. References 

The following references are on 

display at the Dockets Management 

Staff, (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, Rm. 

1061, Rockville, MD 20852, 240–402– 

7500 and are available for viewing by 

interested persons between 9 a.m. and 4 

p.m., Monday through Friday; they also 

are available electronically at https://

www.regulations.gov. Although FDA has 

verified the website addresses in this 

document, please note that websites are 

subject to change over time. 

1. FDA, Market Phase-Out of Grease-Proofing 

Substances Containing PFAS, 

Commitment Letters from Industry 

available at: https://www.fda.gov/food/ 

process-contaminants-food/marketphase-out-grease-proofing-substancescontaining-pfas. 

Dated: December 30, 2024. 

P. Ritu Nalubola, 

Associate Commissioner for Policy. 

[FR Doc. 2024–31692 Filed 1–3–25; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2024–N–5889] 

Request for Nominations of Voting 

Members on a Public Advisory 

Committee; National Mammography 

Quality Assurance Advisory 

Committee 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is requesting 

nominations for voting members to 

serve on the National Mammography 

Quality Assurance Advisory Committee 

in the Center for Devices and 

Radiological Health. Nominations will 

be accepted for current and upcoming 

vacancies effective February 1, 2025, 

with this notice. FDA seeks to include 

the views of women and men, members 

of all racial and ethnic groups, and 

individuals with and without 

disabilities on its advisory committees 

and, therefore, encourages nominations 

of appropriately qualified candidates 

from these groups. 

DATES: Nominations received on or 

before March 7, 2025, will be given first 

consideration for membership on the 

National Mammography Quality 

Assurance Advisory Committee. 

Nominations received after March 7, 

2025, will be considered for nomination 

to the committee as later vacancies 

occur. 

ADDRESSES: All nominations for 

membership should be submitted 

electronically by logging into the FDA 

Advisory Nomination Portal at https://

www.accessdata.fda.gov/scripts/ 

FACTRSPortal/FACTRS/index.cfm or by 

mail to Advisory Committee Oversight 

and Management Staff, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 32, Rm. 5103, Silver Spring, 

MD 20993–0002. Information about 

becoming a member on an FDA advisory 

committee can also be obtained by 

visiting FDA’s website at https://

www.fda.gov/AdvisoryCommittees/ 

default.htm. 

FOR FURTHER INFORMATION CONTACT: 

Regarding all nomination questions for 

membership: James P. Swink, Center for 

Devices and Radiological Health, Food 

and Drug Administration, 10903 New 

Hampshire Ave., Bldg. 66, Rm. 5211, 

Silver Spring, MD 20993, 301–796– 

6313, James.Swink@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: FDA is 

requesting nominations for voting 

members to fill upcoming vacancies on 

the National Mammography Quality 

Assurance Advisory Committee. 

I. General Description of the Committee 

Duties 

The National Mammography Quality 

Assurance Advisory Committee advises 

the Commissioner of Food and Drugs 

(the Commissioner) or designee on: (1) 

developing appropriate quality 

standards and regulations for 

mammography facilities; (2) developing 

appropriate standards and regulations 


khammond on DSK9W7S144PROD with NOTICES
656 Federal Register / Vol. 90, No. 3 / Monday, January 6, 2025 / Notices 

for bodies accrediting mammography 

facilities under this program; (3) 

developing regulations with respect to 

sanctions; (4) developing procedures for 

monitoring compliance with standards; 

(5) establishing a mechanism to 

investigate consumer complaints; (6) 

reporting new developments concerning 

breast imaging that should be 

considered in the oversight of 

mammography facilities; (7) 

determining whether there exists a 

shortage of mammography facilities in 

rural and health professional shortage 

areas and determining the effects of 

personnel on access to the services of 

such facilities in such areas; (8) 

determining whether there will exist a 

sufficient number of medical physicists 

after October 1, 1999; and (9) 

determining the costs and benefits of 

compliance with these requirements. 

II. Criteria for Voting Members 

The committee consists of a core of 15 

members, including the Chair. Members 

and the Chair are selected by the 

Commissioner or designee from among 

physicians, practitioners, and other 

health professionals, whose clinical 

practice, research specialization, or 

professional expertise includes a 

significant focus on mammography. 

Members will be invited to serve for 

overlapping terms of up to 4 years. 

Almost all members of this committee 

serve as Special Government 

Employees. 

III. Nomination Procedures 

Any interested person may nominate 

one or more qualified persons for 

membership on the advisory committee. 

Self-nominations are also accepted. 

Nominations must include a current, 

complete re ́sume ́ or curriculum vitae for 

each nominee, including current 

business address, telephone number, 

and email address if available, and a 

signed copy of the Acknowledgement 

and Consent form available at the FDA 

Advisory Nomination Portal (see 

ADDRESSES). Nominations must specify 

the advisory committee for which the 

nominee is recommended. Nominations 

must also acknowledge that the 

nominee is aware of the nomination 

unless self-nominated. FDA will ask 

potential candidates to provide detailed 

information concerning such matters 

related to financial holdings, 

employment, and research grants and/or 

contracts to permit evaluation of 

possible sources of conflict of interest. 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. 1001 et seq.), and 21 CFR part 14, 

relating to advisory committees. 

Dated: December 30, 2024. 

P. Ritu Nalubola, 

Associate Commissioner for Policy. 

[FR Doc. 2024–31703 Filed 1–3–25; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

National Vaccine Injury Compensation 

Program; List of Petitions Received 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HRSA is publishing this 

notice of petitions received under the 

National Vaccine Injury Compensation 

Program (the Program), as required by 

the Public Health Service (PHS) Act, as 

amended. While the Secretary of HHS is 

named as the respondent in all 

proceedings brought by the filing of 

petitions for compensation under the 

Program, the United States Court of 

Federal Claims is charged by statute 

with responsibility for considering and 

acting upon the petitions. 

FOR FURTHER INFORMATION CONTACT: For 

information about requirements for 

filing petitions, and the Program in 

general, contact Lisa L. Reyes, Clerk of 

Court, United States Court of Federal 

Claims, 717 Madison Place NW, 

Washington, DC 20005, (202) 357–6400. 

For information on HRSA’s role in the 

Program, contact the Director, National 

Vaccine Injury Compensation Program, 

5600 Fishers Lane, Room 8W–25A, 

Rockville, Maryland 20857; (301) 443– 

6593, or visit our website at: http://

www.hrsa.gov/vaccinecompensation/ 

index.html. 

SUPPLEMENTARY INFORMATION: The 

Program provides a system of no-fault 

compensation for certain individuals 

who have been injured by specified 

childhood vaccines. Subtitle 2 of title 

XXI of the PHS Act, 42 U.S.C. 300aa– 

10 et seq., provides that those seeking 

compensation are to file a petition with 

the United States Court of Federal 

Claims and to serve a copy of the 

petition to the Secretary of HHS, who is 

named as the respondent in each 

proceeding. The Secretary has delegated 

this responsibility under the Program to 

HRSA. The Court is directed by statute 

to appoint special masters who take 

evidence, conduct hearings as 

appropriate, and make initial decisions 

as to eligibility for, and amount of, 

compensation. 

A petition may be filed with respect 

to injuries, disabilities, illnesses, 

conditions, and deaths resulting from 

vaccines described in the Vaccine Injury 

Table (the Table) set forth at 42 CFR 

100.3. This Table lists for each covered 

childhood vaccine the conditions that 

may lead to compensation and, for each 

condition, the time period for 

occurrence of the first symptom or 

manifestation of onset or of significant 

aggravation after vaccine 

administration. Compensation may also 

be awarded for conditions not listed in 

the Table and for conditions that are 

manifested outside the time periods 

specified in the Table, but only if the 

petitioner shows that the condition was 

caused by one of the listed vaccines. 

Section 2112(b)(2) of the PHS Act, 42 

U.S.C. 300aa–12(b)(2), requires that 

‘‘[w]ithin 30 days after the Secretary 

receives service of any petition filed 

under section 2111 the Secretary shall 

publish notice of such petition in the 

Federal Register.’’ Set forth below is a 

list of petitions received by HRSA on 

November 1, 2024, through November 

30, 2024. This list provides the name of 

the petitioner, city, and state of 

vaccination (if unknown then the city 

and state of the person or attorney filing 

the claim), and case number. In cases 

where the Court has redacted the name 

of a petitioner and/or the case number, 

the list reflects such redaction. 

Section 2112(b)(2) also provides that 

the special master ‘‘shall afford all 

interested persons an opportunity to 

submit relevant, written information’’ 

relating to the following: 

1. The existence of evidence ‘‘that 

there is not a preponderance of the 

evidence that the illness, disability, 

injury, condition, or death described in 

the petition is due to factors unrelated 

to the administration of the vaccine 

described in the petition,’’ and 

2. Any allegation in a petition that the 

petitioner either: 

a. ‘‘[S]ustained, or had significantly 

aggravated, any illness, disability, 

injury, or condition not set forth in the 

Vaccine Injury Table but which was 

caused by’’ one of the vaccines referred 

to in the Table, or 

b. ‘‘[S]ustained, or had significantly 

aggravated, any illness, disability, 

injury, or condition set forth in the 

Vaccine Injury Table the first symptom 

or manifestation of the onset or 

significant aggravation of which did not 

occur within the time period set forth in 

the Table but which was caused by a 

vaccine’’ referred to in the Table. 

In accordance with section 2112(b)(2), 

all interested persons may submit 

written information relevant to the 

issues described above in the case of the 


khammond on DSK9W7S144PROD with NOTICES